Health Canada has granted approval for the first generic variant of the well-known diabetes medication, Ozempic, marking a significant milestone as Canada becomes the first G7 nation to authorise generic semaglutide. This injectable drug, produced by Dr. Reddy’s Laboratories in India, is intended for once-weekly administration to help manage Type 2 diabetes in adults. In India, it is marketed under the brand name “Obeda.” The approval is expected to provide substantial financial relief for many Canadians who have been grappling with the high costs associated with the brand-name version, which can reach hundreds of pounds monthly.
A Game-Changer for Accessibility
In a recent announcement, Health Canada highlighted that many generic medications are priced 45 to 90 per cent lower than their brand-name counterparts. This is particularly crucial for patients without drug coverage, who have been eagerly anticipating a more affordable option for semaglutide. The soaring cost of Novo Nordisk’s Ozempic has left many individuals struggling to manage their diabetes effectively due to financial constraints.
Health Canada is currently assessing submissions for eight additional generic semaglutide products from various manufacturers. The potential for increased competition in the generic market raises hopes for further cost reductions, which would greatly enhance access for patients.
Understanding the Pricing Structure
The anticipated savings from generic semaglutide depend significantly on the number of alternatives that gain approval and reach the market. According to Mina Tadrous, a pharmaceutical policy expert at the University of Toronto, the initial generic could be priced between 75 to 85 per cent of the brand-name drug. Once a second generic is introduced, prices for both options are expected to drop to around 50 per cent of the brand-name cost. The introduction of a third or more generics could push prices down to approximately 35 per cent of Ozempic’s retail price.
This pricing structure, governed by the pan-Canadian Pharmaceutical Alliance, aims to ensure that Canadians have access to more affordable medications, thereby alleviating the financial burden of managing chronic conditions like diabetes.
The Path to Approval
In March, India’s drug regulatory agency already approved two generic versions of semaglutide from Dr. Reddy’s Laboratories, following the expiration of Novo Nordisk’s patent in that region. The generic semaglutide approved by Health Canada was submitted for review in early 2024 and successfully met the department’s six-month target, excluding additional data requests from the manufacturer.
Health Canada’s statement clarified that generic versions of semaglutide are complex synthetic products that must demonstrate pharmaceutical equivalence to the brand-name drug. The review process ensures that any differences do not compromise the safety, efficacy, or quality of the medication.
“The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the healthcare system,” the department stated.
Why it Matters
The approval of the first generic Ozempic is a groundbreaking development in the landscape of diabetes treatment in Canada. It not only promises significant cost reductions for patients but also sets a precedent for future generic drug approvals. In a healthcare system where affordability is paramount, this move could enhance medication adherence, improve health outcomes for individuals with Type 2 diabetes, and ultimately foster a more equitable healthcare environment. The ripple effects of this decision could resonate throughout the Canadian healthcare system, making critical medications accessible to those who need them most.
